Medical Advocates
HCV Infection/Disease
  Post-Transplant Treatment/Drugs

General Reports
Cyclosporine
Daclizumab   
Interferon
Peg-Interferon alpha-2a
Peg-Interferon alpha-2b
Tacrolimus




 
HCV Liver Transplants Main New/Newsworthy   Home Page    
Last Update:  April 07, 2008
 Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
General Reports
 
          Journal Papers, Abstracts, and Commentaries
 
 
FULL TEXT ARTICLE
 Antihepatitis C virus therapy in liver transplanted patients.
 Picciotto A. 
Ther Clin Risk Manag. 2006 Mar;2(1):39-44.
 Paper
 
Antiviral therapy for hepatitis C virus recurrence after liver transplantation in
HIV-infected patients: outcome in the Bonn cohort.
 Wojcik K, Vogel M, Voigt E, et al
AIDS. 2007 Jun;21(10):1363-1365.
 Abstract
 
Antiviral treatment withdrawal in viremic HCV-positive liver transplant patients: impact on viral
loads, allograft function and morphology.
Kornberg A, Kupper B, Tannapfel A, et al
 Liver Int. 2006 Sep;26(7):811-6.
Abstract
 
Sensitivity to antiviral therapy may change after liver transplantation in patients with
chronic hepatitis C virus infection.
Feliu A, Carrion JA, Massaguer A, et al
J Viral Hepat. 2006 Aug;13(8):544-51.
 Abstract
 
Impact of double-filtration plasmapheresis in combination with interferon and ribavirin in living
donor liver transplant recipients with hepatitis C.
 Taniguchi M, Furukawa H, Shimamura T, et al
Transplantation. 2006 Jun 27;81(12):1747-9.
 Abstract
 
Antiviral therapy for hepatitis C virus recurrence following liver transplantation: long-term results
from a single center experience.
Burra P, Targhetta S, Pevere S, et al
Transplant Proc. 2006 May;38(4):1127-30.
Abstract
 
Complete weaning off immunosuppression in HCV liver transplant recipients
is feasible and favourably impacts on the progression of disease recurrence.
Tisone G, Orlando G, Cardillo A, Palmieri G, et al
J Hepatol. 2006 Apr;44(4):627-9.
Abstract
 
Immunosuppression for liver transplantation in HCV-infected patients: mechanism-based
principles.
Eghtesad B, Fung JJ, Demetris AJ, et al
Liver Transpl. 2005 Nov;11(11):1343-52.
 Abstract
Cyclosporine
 

          Journal Papers, Abstracts, and Commentaries
 
 
Intentional conversion from tacrolimus to cyclosporine for HCV-positive patients on preemptive
interferon therapy after living donor liver transplantation.
 Eguchi S, Takatsuki M, Soyama A, et al  
 Ann Transplant. 2007;12(4):11-5.
 Abstract
 
Hepatitis C virus viral load after conversion from tacrolimus to cyclosporine in liver
transplant patients:a pilot study.
 Guitard J, Sandres-Sauné K, et al  
 Transplant Proc. 2007 Oct;39(8):2603-5.
 Abstract
 
FULL-TEXT ARTICLE
Cyclosporine versus tacrolimus in patients with HCV infection after liver transplantation:
effects on virus replication and recurrent hepatitis.
Hilgard P, Kahraman A, Lehmann N, et al
World J Gastroenterol. 2006 Feb 7;12(5):697-702
Paper
Daclizumab
 

     Journal Papers, Abstracts, and Commentaries

  Corticosteroid-free immunosuppression with daclizumab in HCV(+) liver transplant recipients:
1-year interim results of the HCV-3 study.
 Klintmalm GB, Washburn WK, Rudich SM, et al
 Liver Transpl. 2007 Oct 29;13(11):1521-1531
 Abstract
 
Interferon
Peg-Interferon alph-2a                  Peg-Interferon alpha-2b

          Journal Papers, Abstracts, and Commentaries
 
Relapse response to interferon and ribavirin in liver transplant recipient with hepatitis C
recurrence.
Coccoli P, Cordone G, Bruno M, Parrilli G.
Transplant Proc. 2005 Dec;37(10):4406-7.
Abstract

Peginterferon alfa-2a
 
          Journal Papers, Abstracts, and Commentaries
 
  Impact of pegylated interferon alfa-2a and ribavirin on hepatic fibrosis in liver
transplant patients with recurrent hepatitis C: an open-label series.
Mukherjee S, Lyden E.
Hepatogastroenterology. 2006 Jul-Aug;53(70):561-5
 Abstract
 
Peginterferon alfa-2a for hepatitis C after liver transplantation: Two randomized, controlled
trials.
 Chalasani N, Manzarbeitia C, Ferenci P, et al  
Hepatology. 2005 Jan 19;41(2):289-298
Abstract
 
Pegylated interferon alfa-2a and ribavirin for recurrent hepatitis C after liver transplantation.
Mukherjee S.
 Transplant Proc. 2005 Dec;37(10):4403-5.
 Abstract
Peg Interferon alfa–2b
 

          Journal Papers, Abstracts, and Commentaries
 
 
Limited Benefit of Biochemical Response to Combination Therapy for Patients With
Recurrent Hepatitis C After Living-Donor Liver Transplantation.
Ueda Y, Takada Y, Haga H,et al
Transplantation. 2008 Mar 27;85(6):855-862.
 Abstract
 
Treatment of Patients with Recurrent Hepatitis C after Liver Transplantation with Peginterferon
Alfa-2B Plus Ribavirin.
Neumann U, Puhl G, Bahra M, et al
Transplantation. 2006 Jul 15;82(1):43-47.
 Abstract
 
Plasma ribavirin concentrations during treatment of recurrent hepatitis C with peginterferon
alpha-2b and ribavirin combination after liver transplantation.
 Dumortier J, Ducos E, Scoazec JY, et al
 J Viral Hepat. 2006 Aug;13(8):538-43.
 Abstract
 
HCV clearance and treatment outcome in genotype 1 HCV-monoinfected, HIV-coinfected and
liver transplanted patients on peg-IFN-alpha-2b/ribavirin.
Moreno A, Barcena R, Garcia-Garzon S, et al
J Hepatol. 2005 Nov;43(5):783-90
 Abstract
 
Pilot study of pegylated interferon alfa-2b and ribavirin for recurrent hepatitis C after liver
transplantation.
 Mukherjee S, Rogge J, Weaver L, Schafer DF.et al 
Transplant Proc. 2003 Dec;35(8):3042-4.
Abstract
Tacrolimus
 

          Journal Papers, Abstracts, and Commentaries
 
 
Rejection rates in a randomised trial of tacrolimus monotherapy versus triple therapy
in liver transplant recipients with hepatitis C virus cirrhosis.
Samonakis DN, Mela M, Quaglia A
Transpl Infect Dis. 2006 Mar;8(1):3-12.
Abstract
 
FULL-TEXT ARTICLE
Cyclosporine versus tacrolimus in patients with HCV infection after liver transplantation:
effects on virus replication and recurrent hepatitis.
Hilgard P, Kahraman A, Lehmann N, et al
World J Gastroenterol. 2006 Feb 7;12(5):697-702
Paper
 
A prospective randomized trial comparing tacrolimus and steroids with tacrolimus monotherapy
in liver transplantation: the impact on recurrence of hepatitis C
Margarit C, Bilbao I, Castells L, et al
Transpl Int. 2005 Dec;18(12):1336-45.
 Abstract
 

HCV Liver Transplants Main New/Newsworthy   Home Page    

Post– Transplant Treatment/Drugs